Physician profile
William B Keller
NPI 1033259296
$12,574.80
in general payments reported to CMS, 2019-2025
47 companies · $1,776 in 2025
The $1,776 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,585 · 2022: $2,762 · 2023: $2,872 · 2024: $2,579 · 2025: $1,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,227.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,473.48 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,035.46 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $849.69 | 2021-2025 | |
| Amgen INC. | $793.18 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $753.12 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $735.44 | 2021-2025 | |
| Esperion Therapeutics, INC. | $656.07 | 2021-2025 | Nexletol |
| Pfizer INC. | $632.09 | 2021-2025 | |
| Radius Health, INC. | $492.87 | 2021-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.95 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $438.28 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $386.50 | 2021-2025 | Breztri, Fasenra, Farxiga |
| Kowa Pharmaceuticals America, INC. | $382.99 | 2021-2025 | Seglentis, Livalo, Zoryve |
| Xeris Pharmaceuticals, INC. | $289.13 | 2022-2025 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $283.76 | 2022-2023 | Hetlioz |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $277.57 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| E.R. Squibb & Sons, L.L.C. | $277.16 | 2022-2024 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $254.00 | 2021-2023 | |
| Astellas Pharma US INC | $220.19 | 2021-2025 | Veozah |
| Merck Sharp & Dohme LLC | $202.00 | 2021-2023 | Belsomra, Steglatro, Lagevrio |
| Dexcom, INC. | $178.72 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $177.06 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Almatica Pharma LLC | $144.69 | 2022-2023 | Sertraline Hcl, Loreev Xr, Gralise |
| Sumitomo Pharma America, INC. | $131.93 | 2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $114.70 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.01 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.55 | 2021-2022 | |
| Amarin Pharma, INC. | $104.19 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.88 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $78.50 | 2021-2022 | |
| Halozyme INC | $54.98 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $43.27 | 2021 | |
| Horizon Therapeutics Plc | $40.17 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $38.44 | 2024 | Voquezna |
| Djo, LLC | $33.64 | 2023 | Cmf |
| Idorsia Pharmaceuticals US INC | $32.94 | 2023-2024 | Quviviq |
| Nestle Healthcare Nutrition INC. | $24.72 | 2021-2022 | |
| Exact Sciences Corporation | $23.70 | 2025 | The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $21.52 | 2021 | |
| Convatec INC. | $20.55 | 2025 | |
| Corcept Therapeutics | $20.03 | 2023 | Korlym |
| Eisai INC. | $15.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.46 | 2022 | |
| Adlon Therapeutics L.P. | $14.21 | 2021 | |
| Cleerly, INC. | $13.81 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Mylan Specialty L.P. | $13.29 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.04 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.